Skip to content


  • Letter
  • Open Access

Not all β-lactams are equal regarding neurotoxicity

  • Khalil Chaïbi1,
  • Maïté Chaussard1, 2,
  • Sabri Soussi1, 2,
  • Matthieu Lafaurie4 and
  • Matthieu Legrand1, 2, 3Email author
Critical Care201620:350

Published: 27 October 2016

The original article was published in Critical Care 2016 20:220


Intensive Care UnitStatus EpilepticusImipenemTrough LevelCefepime

We read with interest the letter from May et al. recently published in Critical Care [1]. The authors suggest that overdosing of β-lactams in 108 critically ill patients receiving renal replacement therapy may not be associated with neurotoxicity. We agree that adequate plasmatic levels of β-lactams in critically ill patients with sepsis should be a primary goal and that under-dosing may put the patient at a dangerous risk of treatment failure [2]. We are, however, concerned about the conclusions of this letter and would like to comment on two points.

First, not all β-lactams are equal regarding neurotoxicity, and some may expose the patient to higher risk. A number of studies have reported neurotoxicity of imipenem, especially in patients with brain injury [3, 4]. More recently, several authors have reported neurotoxicity with cefepime. Fugate et al. reported that 7 % to 15 % of critically ill patients treated with cefepime developed definitive or possible neurotoxicity [5]. Hence, renal insufficiency was a major risk factor. We have also observed over the last 2 years similar findings with four cases of cefepime-related neurotoxicity in our intensive care unit (ICU) in patients with chronic renal insufficiency or acute kidney injury.

Second, May et al. defined neurotoxicity as an association of overdose and convulsions. There is, however, strong evidence showing that neurotoxicity of β-lactams can present without seizures [6]. Cefepime-related neurotoxicity has been reported to present mostly as myoclonus and impaired consciousness, confusion, hallucinations, or agitation. Convulsions might be only the most extreme manifestation of the induced encephalopathy toxicity. In our cases, the neurological manifestations were loss of contact, agitation, disorientation and, for two of them, myoclonic twitches and jerks. The observed cefepime trough level of those patients during these events ranged from 144 mg/l to 455 mg/l for an upper therapeutic trough level of 90 mg/l according to our laboratory, while daily doses were 4 to 6 g/day. An electroencephalogram was carried out for each patient and has objectified a toxic encephalopathy pattern or aspecific slow waves with no sign of lobe epilepsy. Every patient experienced a regression of the symptoms with the withdrawal of the offending drug.

To conclude, while we agree that high serum levels of β-lactams should be obtained at the initiation of antibiotic therapy in patients with sepsis, intensivists should not overlook the potential neurotoxicity of some β-lactams with a low therapeutic index such as imipenem and cefepime. The risk of cefepime neurotoxicity should not be underappreciated in patients with neurological symptoms, especially if renal function is impaired.

Authors’ response

  • Faten May,
  • Najouah El-Helali,
  • Jean-François Timsit and
  • Benoît Misset
  • We thank Dr Chaïbi et al. for their valuable and insightful comments on our report of the low evidence for an association between supra-therapeutic serum levels of β-lactams (BL) and clinical toxicity in ICU patients with acute renal failure (ARF) treated with intermittent hemodialysis [1].

    Chaïbi et al. point out that neurotoxicity is common among BL, especially in at-risk patients such as those with ARF, and that some BL with a low therapeutic index may induce more neurological events. Several reports described an increased risk for penicillins, imipenem, and fourth generation cephalosporins, and suggested that neurological complications may range from confusion, depressed level of consciousness, and non-specific encephalopathy to myoclonus, non-convulsive status epilepticus (NCSE), and seizures [6].

    We would like to draw attention to the fact that the majority of those articles were non-human experimental studies, case series, and retrospective reviews, with assessment offering low levels of evidence [7]. To establish a cause-effect relationship between a BL administration and clinical signs of encephalopathy remains a major difficulty because both clinical and electrical signs are non-specific. All the neurological symptoms of clinical encephalopathy may be observed in conditions such as metabolic abnormality, uremic disorder, ICU delirium, withdrawal syndrome, or septic encephalopathy, which are very frequent in ICU septic patients [8].

    In our population, while we may have missed non-convulsive signs and NCSE, we could not find an association between convulsions and BL observed at the supra-therapeutic level.

    Therefore, despite the comments of Chaïbi et al., we consider that the BL neurotoxic threshold is not yet well identified and is still challenging. A proper diagnosis of BL neurological toxicity may be obscured by the overall clinical picture and may easily be attributed to the infectious process or to an underlying metabolic. We estimate that prospective observational studies, including pre-established and precise definitions and design, are still needed to assess BL encephalopathy and the neurotoxic threshold and to conclude on their clinical impact.






    Intensive care unit


    Acute renal failure


    Non-convulsive status epilepticus


    Availability of data and materials


    Authors’ contributions

    KC and ML wrote the first draft of the manuscript. All authors read and approved the final manuscript.

    Competing interests

    The authors declare that they have no competing interests.

    Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

    Authors’ Affiliations

    Department of Anesthesiology and Critical Care and Burn Unit, St-Louis Hospital, Assistance Publique- Hopitaux de Paris, Paris, France
    University Paris Diderot, Paris, France
    UMR INSERM 942, Institut National de la Santé et de la Recherche Médicale (INSERM), Lariboisière Hospital University Paris Diderot, Paris, France
    AP-HP, Infectious disease, St-Louis Hospital, Paris, France


    1. May F, El-Helali N, Timsit J-F, Misset B. Absence of obvious link between supra-therapeutic serum levels of β lactams and clinical toxicity in ICU patients with acute renal failure treated with intermittent hemodialysis. Crit Care. 2016;20:220.View ArticlePubMedPubMed CentralGoogle Scholar
    2. Honore PM, Spapen HD. Cefepime-induced neurotoxicity in critically ill patients undergoing continuous renal replacement therapy: beware of dose reduction! Crit Care. 2015;19:455.View ArticlePubMedPubMed CentralGoogle Scholar
    3. Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller M-D, Berger MM, et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010;14:R51.View ArticlePubMedPubMed CentralGoogle Scholar
    4. Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015;85:1332–41.View ArticlePubMedGoogle Scholar
    5. Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EFM, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17:R264.View ArticlePubMedPubMed CentralGoogle Scholar
    6. Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, Calandra T, Marchetti O. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54(10):4360–7.View ArticlePubMedPubMed CentralGoogle Scholar
    7. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72(3):381–93.View ArticlePubMedPubMed CentralGoogle Scholar
    8. Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology. 2016;86(10):963–71.View ArticlePubMedGoogle Scholar


    © The Author(s). 2016